ProPublica has launched a call for public submissions to investigate the continued use of prior authorization by major health insurers. The initiative follows industry pledges made last year to reduce the practice after widespread backlash from patients, providers, and politicians. The newsroom seeks to determine if these commitments have translated into tangible changes for patients covered by Medicaid, Medicare, the Children’s Health Insurance Program, and the Affordable Care Act marketplace.

Prior authorization requires insurers to approve medical expenses before coverage is granted. ProPublica reporting has previously identified that this process can delay or deny critical medical care, tests, equipment, and medication. While major insurers publicly vowed to curb its use, data from last year indicates the industry continues to rely heavily on the approval mechanism. The current investigation aims to document the real-life impact of these denials through patient and provider experiences.

What the Left Is Saying

Progressive advocates and patient rights groups have long characterized prior authorization as a bureaucratic barrier that prioritizes insurer profits over patient health. They argue that the process disproportionately affects vulnerable populations, including those on Medicaid and Medicare, who may face significant delays in receiving necessary treatments. Advocates contend that despite industry promises, the systemic friction in the approval process remains a primary obstacle to accessible healthcare. ProPublica’s outreach to patients with these specific coverage types underscores the concern that low-income and elderly populations bear the brunt of these administrative hurdles.

What the Right Is Saying

Conservative commentators and industry stakeholders often frame prior authorization as a necessary tool for managing healthcare costs and preventing unnecessary procedures. They argue that without such checks, medical spending could spiral out of control, driving up premiums for all consumers. From this perspective, the process ensures that treatments are medically necessary and evidence-based before public or private funds are expended. ProPublica’s inclusion of insurance company employees and regulators in its data collection reflects an effort to understand the operational and regulatory constraints that insurers cite when defending the continued use of these approvals.

What the Numbers Show

According to ProPublica, data from last year indicates that the health insurance industry is still relying heavily on prior authorization, despite public pledges to reduce its use. The newsroom is specifically seeking accounts from individuals covered by Medicaid, Medicare, the Children’s Health Insurance Program, or the Affordable Care Act marketplace. Employer-sponsored insurance respondents are excluded from this specific phase of the investigation. ProPublica notes that while the team may not respond to every submission, all entries will be reviewed, and consent will be required before publishing any personal stories.

The Bottom Line

This investigation highlights the gap between industry promises and operational reality in the U.S. healthcare system. As ProPublica gathers qualitative data from patients and providers, the findings could inform future regulatory debates and legislative efforts regarding insurance practices. The newsroom plans to analyze these submissions to determine if prior authorization continues to lead to delayed or missed treatments, potentially influencing public perception and policy discussions on healthcare accessibility.